Table 2 FSHR expression in blood vessels associated with cancer metastases (n = 209)
From: Expression of follicle-stimulating hormone receptor by the vascular endothelium in tumor metastases
Type of cancer | Metastases to: | Number of cases | FSHR immunostained vessels | |||
|---|---|---|---|---|---|---|
No staining | Positive staining | FSHR-positive vessels/mm2 | ||||
Inside the tumor | Outside the tumor | |||||
Prostate | Brain | 3 | 1 (33%) | 2 (67%) | 38.8 ± 13.5 | 117.8 ± 4.5 |
Lymph node | 33 | 9 (27%) | 24 (63%) | 30.3 ± 17.1 | 74.7 ± 2.8 | |
Bone | 40 | 26 (65%) | 14 (35%) | 33.0 ± 14.4 | 90.3 ± 6.5 | |
Breast | Brain | 12 | 0 | 12 (100%) | 98.4 ± 12.6 | 104.4 ± 4.9 |
Pleura | 27 | 0 | 27 (100%) | 68. 7 ± 10. 4 | ND | |
Liver | 3 | 0 | 3 (100%) | 100. 5 ± 14. 4 | 95. 2 ± 7. 9 | |
Kidney | Brain | 5 | 1 (20%) | 4 (80%) | 132. 7 ± 11. 6 | 108. 4 ± 9. 9 |
Colon | Brain | 11 | 1 (9%) | 10 (91%) | 87. 6 ± 20. 1 | 91. 1 ± 5. 8 |
Liver | 23 | 1 (4%) | 22 (96%) | 107. 6 ± 20. 4 | 112. 0 ± 12. 0 | |
Lung | Brain | 46 | 4 (9%) | 42 (91%) | 115. 1 ± 17. 8 | 131. 1 ± 7. 1 |
Uterine corpus leiomyo-sarcoma | Lung | 6 | 0 | 6 (100%) | 56.5 +/- 9.7 | 97. 9 ± 10. 9 |